VERVE THERAPEUTICS INC(NASDAQ:VERV) stock News

VERV Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Chartmill

Verve Therapeutics Inc (NASDAQ:VERV): A High-Growth Momentum Stock Aligned with Minervini’s Trend Model

10 days ago - By: Eli Lilly and Company - Mentions: LLY

Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

11 days ago - By: Eli Lilly and Company - Mentions: LLY

Lilly and Verve announce expiration of Verve tender offer

12 days ago - By: Yahoo Finance - Mentions: LLY

Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition

14 days ago - By: MarketBeat - Mentions: URGN NKTR

3 Bullish Biotech Stocks With Explosive Growth Trends

20 days ago - By: MarketBeat - Mentions: KSS NTLA GOGO LLY ...

Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook

25 days ago - By: Yahoo Finance - Mentions: LLY

Verve Therapeutics, Inc. (VERV): A Bull Case Theory

a month ago - By: Brodsky & Smith LLC - Mentions: SAGE CTLP NYSE LLY ...

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)

a month ago - By: The Motley Fool - Mentions: LLY

Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week

a month ago - By: Halper Sadeh LLC - Mentions: CTLP CVAC

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLP, VERV, CVAC on Behalf of Shareholders

2 months ago - By: Kahn Swick & Foti, LLC

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV

2 months ago - By: Yahoo Finance - Mentions: LLY VZ

Verve Therapeutics downgraded to Hold from Buy at Canaccord

2 months ago - By: Benzinga

5 Analysts Assess Verve Therapeutics: What You Need To Know

2 months ago - By: Halper Sadeh LLC - Mentions: SAGE CTLP SOAR

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VERV, SAGE, CTLP, SOAR on Behalf of Shareholders

2 months ago - By: Brodsky & Smith LLC - Mentions: SAGE CTLP SOAR LLY ...

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)

2 months ago - By: Halper Sadeh LLC

VERV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verve Therapeutics, Inc. Is Fair to Shareholders

2 months ago - By: Yahoo Finance - Mentions: LLY

Why Verve Therapeutics Stock Is Skyrocketing Today

2 months ago - By: The Motley Fool - Mentions: LLY

Why Verve Therapeutics Stock Is Skyrocketing Today

2 months ago - By: Yahoo Finance - Mentions: LLY

Eli Lilly Strikes up to $1.3 Billion Deal to Buy Verve Therapeutics

2 months ago - By: Investor's Business Daily - Mentions: LLY NTLA EDIT CRSP ...

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover

2 months ago - By: Benzinga - Mentions: RGC SAGE

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

2 months ago - By: Ademi & Fruchter LLP

Shareholder Alert: The Ademi Firm Investigates Whether Verve Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

2 months ago - By: Yahoo Finance - Mentions: LLY KHC BEAM NTLA

Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B

2 months ago - By: Yahoo Finance - Mentions: JBL LZB UBS BAC

VERVE THERAPEUTICS INC (VERV) Stock News

VERV Latest News, Press Relases and Analysis

Verve Therapeutics Inc (NASDAQ:VERV): A High-Growth Momentum Stock Aligned with Minervini’s Trend Model

Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

Lilly and Verve announce expiration of Verve tender offer

Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition

3 Bullish Biotech Stocks With Explosive Growth Trends

Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook

Verve Therapeutics, Inc. (VERV): A Bull Case Theory

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)

Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLP, VERV, CVAC on Behalf of Shareholders

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV

Verve Therapeutics downgraded to Hold from Buy at Canaccord

5 Analysts Assess Verve Therapeutics: What You Need To Know

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VERV, SAGE, CTLP, SOAR on Behalf of Shareholders

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)

VERV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verve Therapeutics, Inc. Is Fair to Shareholders

Why Verve Therapeutics Stock Is Skyrocketing Today

Why Verve Therapeutics Stock Is Skyrocketing Today

Eli Lilly Strikes up to $1.3 Billion Deal to Buy Verve Therapeutics

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

Shareholder Alert: The Ademi Firm Investigates Whether Verve Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B

How To Earn $500 A Month From La-Z-Boy Stock Ahead Of Q4 Earnings